Amgen Inc (AMGN) Fair Value & Analysis
Healthcare · US · Market cap $187B
Amgen Inc
AMGN · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $261.17 to $252.02 (−3.5%) since Jun 23, 2026. Share price +14.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $246.15 – $357.31 · fair‑value band $138.86 – $339.52 · the $347.01 price screens above the $252.02 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Amgen Inc (AMGN) currently trades at $347.01, while our model-based Fair Value estimate is $252.02 — implying the stock looks roughly 27.4% overvalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Amgen Inc generated revenue of $37.2B at a net margin of 21.0%. Revenue grew 5.8% year over year. It earns a return on equity of 101.3%. Net debt stands at $45.5B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amgen Inc reported revenue of $36.7B in FY2025 versus $26.0B in FY2021, a compound +9.1%/yr. Reported net income was $7.7B in FY2025, compounding +7.0%/yr from FY2021.
Is AMGN fairly valued? → Check now
Recent news
- UBS, BofA, Jefferies Start Quantinuum With Buy Ratings On 'Full-Stack' Platform
- Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next.
- FDA commissioner contenders down to three - report
- Medicare GLP-1 Bridge: What to expect
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 2,944 MXN | -29% |
| Johnson & Johnson, JNJB34 | R$78.55 | R$12.18 | -84% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRK | $119.09 | $77.57 | -35% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amgen Inc (AMGN) undervalued?
What is the fair value of AMGN?
What is the quality score of AMGN?
What is the revenue of Amgen Inc (AMGN)?
What is the net profit margin of AMGN?
Does Amgen Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.